1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Standex reported fiscal third-quarter 2025 results for the quarter ended March 31, 2025, with net sales up 17.2% to $207.8 million, helped by acquisitions, and GAAP diluted EPS of $1.81 versus $1.35 a year earlier. Adjusted diluted EPS rose 3.7% to $1.95, while free cash flow fell to $3.5 million from $19.3 million and net debt rose to $470.4 million from $10.0 million.
Net sales $207.8 million, up 17.2% year over year, with the Electronics segment up 38.4% to $111.3 million
GAAP operating income $26.3 million, up 20.2%; adjusted operating margin 19.4% versus 16.6%
Adjusted diluted EPS $1.95 versus $1.88; free cash flow $3.5 million versus $19.3 million
Net debt $470.4 million at March 31, 2025, versus $10.0 million a year earlier; fourth-quarter revenue expected slightly to moderately higher sequentially
Five Below raised its first-quarter fiscal 2025 guidance on May 2, 2025, expecting net sales of about $967 million and diluted EPS of $0.69 to $0.71, both above prior ranges. Co-founder and Executive Chair Tom Vellios will not stand for re-election at the June 12, 2025 annual meeting and will move to an advisory role through the end of 2025, while director Mike Devine is expected to become non-executive Chair.
Q1 net sales now expected at about $967 million, up from prior guidance of $905 million to $925 million
Q1 diluted EPS now expected at $0.69 to $0.71, up from $0.44 to $0.55; adjusted EPS $0.82 to $0.84, up from $0.50 to $0.61
Comparable sales now expected to rise about 6.7%, versus prior guidance of flat to 2% growth
Vellios's Executive Chair role ends at the June 12, 2025 annual meeting; Mike Devine is expected to be appointed non-executive Chair if re-elected
IES Holdings reported fiscal 2025 second-quarter revenue of $834 million, up 18%, and diluted earnings per share of $3.50, up from $2.29 a year earlier. Growth was led by the Communications and Infrastructure Solutions segments, while Residential revenue and operating income declined.
Revenue of $834 million for the quarter ended March 31, 2025, up 18% from $706 million
Net income attributable to IES of $70.7 million, up 34% from $52.9 million; diluted EPS $3.50 vs. $2.29
Residential revenue fell 6% to $317.9 million, and segment operating income fell to $22.7 million from $34.7 million
Backlog of approximately $1.8 billion as of March 31, 2025, up from $1.363 billion a year earlier
Cboe Global Markets reported record first-quarter 2025 net revenue of $565.2 million, up 13% from a year earlier, and diluted EPS of $2.37, up 21%. The company raised its 2025 organic total net revenue growth target to mid to high single digits from mid single digits, which signals stronger expected top-line growth for shareholders.
Net revenue of $565.2 million, up 13% from $502.1 million in Q1 2024; the release describes this as a record
Diluted EPS of $2.37, up 21%; adjusted diluted EPS of $2.50, up 16%
2025 organic total net revenue growth target raised to mid to high single digits from mid single digits; adjusted operating expense guidance reaffirmed at $837 to $852 million
Paid $66.4 million in cash dividends ($0.63 per share) and repurchased $30.0 million of stock in Q1; about $649.8 million of repurchase authorization remained at March 31, 2025
Piper Sandler reported first quarter 2025 results on May 2, 2025. Net revenues were $357.3 million, up 4% from a year earlier but down 26% from the fourth quarter of 2024, and diluted EPS was $3.65 on a U.S. GAAP basis, up 50% year over year. Results were held back by a $29.6 million investment loss, and the company also declared a $0.65 quarterly dividend.
Net revenues of $357.3 million rose 4% year over year and fell 26% from the fourth quarter of 2024.
Advisory services revenues of $216.8 million rose 38% year over year.
Diluted EPS was $3.65 (U.S. GAAP) and $4.09 (adjusted), versus $2.43 and $2.79 in the first quarter of 2024.
Board declared a $0.65 per share quarterly dividend, payable June 13, 2025 to holders of record on May 30, 2025.
nVent reported first-quarter 2025 net sales of $809 million, up 11%, with reported EPS from continuing operations of $0.52, up 2%, and adjusted EPS of $0.67, up 10%. The company raised full-year 2025 reported sales growth guidance to 19% to 21% from 8% to 10%, and adjusted EPS guidance to $3.03 to $3.13 from $2.98 to $3.08, with the raised sales range including the Avail Electrical Products Group acquisition. Organic sales grew 2% and operating income fell 1%, so the higher guidance rests partly on acquisitions and currency-neutral growth was modest.
Q1 net sales of $809 million, up 11%; organic sales up 2%
Reported EPS from continuing operations of $0.52, up 2%; adjusted EPS of $0.67, up 10%
Full-year 2025 adjusted EPS guidance raised to $3.03 to $3.13 from $2.98 to $3.08
Q1 operating income of $130 million, down 1%; free cash flow of $44 million, up 32%
Amneal Pharmaceuticals reported first-quarter 2025 net revenue of $695 million, up 5% from $659 million a year earlier, and net income attributable to the company of $12 million, compared with a net loss of $92 million in the first quarter of 2024. The company reaffirmed its full-year 2025 guidance, including net revenue of $3.0 billion to $3.1 billion and adjusted diluted EPS of $0.65 to $0.70, so shareholders see improved results with no change to the outlook.
Net revenue $695 million, up 5% from $659 million; Affordable Medicines up 6%, Specialty up 3%, AvKARE up 6%
GAAP diluted EPS $0.04 versus a loss of $0.30; adjusted diluted EPS $0.21, up 50% from $0.14
Adjusted EBITDA $170 million, up 12% from the prior-year quarter
Full-year 2025 guidance affirmed: adjusted EBITDA $650 million to $675 million; conference call at 8:30 am Eastern on May 2, 2025
The Cigna Group reported first quarter 2025 results, with total revenues up 14% to $65.5 billion and shareholders' net income of $1.3 billion, or $4.85 per share, compared with a net loss a year earlier. The company raised its full-year 2025 adjusted income from operations outlook to at least $29.60 per share, up $0.10, which supports earnings expectations for shareholders.
Total revenues rose 14% to $65.5 billion; shareholders' net income was $1.3 billion, or $4.85 per share, versus a $0.3 billion loss ($0.97 per share) in Q1 2024.
Adjusted income from operations was $1.8 billion, or $6.74 per share, compared with $6.47 per share in Q1 2024.
Cigna Healthcare adjusted pre-tax income fell 4% to $1.3 billion, with the medical care ratio rising to 82.2% from 79.9%.
The company completed the sale of its Medicare businesses to HCSC on March 19, 2025, and repurchased 8.2 million shares for about $2.6 billion year to date through May 1, 2025.
BrightSpring reported first quarter 2025 results on May 2, 2025, with net revenue of $2,878 million, up 25.9%, and net income from continuing operations of $9.2 million, compared with a loss of $56.0 million a year earlier. The company raised its full-year 2025 revenue guidance to $12,000 million to $12,500 million and Adjusted EBITDA guidance to $570 million to $585 million, and said the planned sale of its Community Living business to Sevita remains on track this year.
Net revenue of $2,878 million, up 25.9% from $2,286 million in Q1 2024
Net income from continuing operations of $9.2 million, versus a net loss from continuing operations of $56.0 million in Q1 2024
Adjusted EBITDA of $131 million, up 28.2% from $102 million
2025 guidance raised: revenue of $12,000 million to $12,500 million; Adjusted EBITDA of $570 million to $585 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.